MMEA
BBIO icon

Main Management ETF Advisors’s BridgeBio Pharma BBIO Stock Holding History

Main Management ETF Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,537
Closed -$2.34M – 124
2025
Q4 		$2.34M Buy
30,537
+312
+1% +$20.5K 0.08% 41
2025
Q3 		$1.57M Buy
30,225
+7,502
+33% +$366K 0.06% 75
2025
Q2 		$981K Buy
22,723
+372
+2% +$13.5K 0.04% 89
2025
Q1 		$773K Buy
+22,351
New +$754K 0.04% 93

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Main Management ETF Advisors's BBIO Position: Q1 2026 in Review

Main Management ETF Advisors sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 30,537 shares — an estimated $2.34M sold.

Main Management ETF Advisors first reported a position in BBIO in Q1 2025 and held it in 4 quarters. The position peaked at $2.34M in Q4 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Main Management ETF Advisors reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Main Management ETF Advisors sold 30,537 BridgeBio Pharma shares in Q1 2026, an estimated $2.34M.
  • Main Management ETF Advisors first reported a position in BridgeBio Pharma in Q1 2025 and held it in 4 quarters.
  • Main Management ETF Advisors's BridgeBio Pharma position peaked at $2.34M in Q4 2025.
  • 460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Main Management ETF Advisors's 13F filing for Q1 2026, filed 15 May 2026.